Figure 6.

The PaSSS-based drug combinations stopped tumor growth in vivo. MDA-MB-468 (A,B) or MDA-MB-231; (C) cells were injected subcutaneously into mice, and once tumors reached 80 mm³, treatments were initiated. In both cases, the PaSSS-based drug combinations, predicted to collapse the cell line-specific altered signaling signature, inhibited the tumor growth and demonstrated an effect superior to monotherapies or combinations predicted to target partially the PaSSS (see Figure 2 for details regarding the altered signaling signatures and the PaSSS-based drug combinations). The values are mean ±  S.E. for at least n = 8 for each condition. (Abbreviations: Er—Erlotinib, Tr—Trametinib, 2DG—2 deoxyglucose, Tam—Tamoxifen, Taxol—Paclitaxel, PaSSS—Patient- specific signaling signature, *—Predicted combination, S.E. —Standard error, n—no of mice).